University of Toronto, Canada
Dr. Eleftherios P. Diamandis, M.D., Ph.D., FRCPC serves as an Advisor of Panacea Pharmaceuticals, Inc. Dr. Diamandis serves as Professor and Head of the Division of Clinical Biochemistry in Department of Laboratory Medicine and Pathobiology at Faculty of Medicine in University of Toronto based in Toronto, Ontario, Canada. He serves as Division Head of Clinical Biochemistry in the Department of Pathology and Laboratory Medicine at Mount Sinai Hospital and Biochemist-in-chief at the University Health Network and Toronto Medical Laboratories. Dr. Diamandis serves as a Member of Clinical and Scientific Advisory Board of Novx Systems Inc. He serves as a Member of Scientific Advisory Board of Diagnostic Systems Laboratories, Inc. He serves as a Member of Advisory Board of AutoGenomics Inc. and served as a Member of Advisory Board of Panacea Global, Inc. Dr. Diamandis has been active in the field of cancer diagnostics for over 20 years. He serves as the Chair of the National Academy of Clinical Biochemistry effort to develop guidelines for the clinical use of tumor markers. His most recent research focuses on proteomic methodologies for identifying novel cancer biomarkers and the physiology of kallikrein enzymes, as they relate to cancer initiation and progression. He is also conducting research to validate multiparametric panels for early ovarian, breast, and prostate cancer diagnosis. Dr. Diamandis serves on the boards of 25 journals. Dr. Diamandis received the Education Excellence Award from the Canadian Society of Clinical Chemistry in 2003. He received 2007 The Morton K. Schwartz Award for Significant Contributions in Cancer Research Diagnostics. He serves on the editorial boards of numerous journals. He has published more than 400 original papers and holds 13 patents, with another 20 pending. He co-authored a recent textbook, Tumor Markers. For many years, he has run workshops on tumor markers and proteomic technologies at the AACC annual meetings. Dr. Diamandis' current focus is in the area of proteomics and biomarkers used in the detection and treatment of various cancers. Dr. Diamandis received his Ph.D. and M.D. from the University of Athens, and a Diploma in Clinical Biochemistry from the U of T.
Discovery and validation of novel cancer biomerkers by using mass spectrometry; role of kallikrein enzymes in health and disease; basic and translational aspects of tumour metastasis.